Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

107.17
-5.3600-4.76%
Post-market: 107.170.00000.00%19:30 EDT
Volume:441.21K
Turnover:47.60M
Market Cap:7.38B
PE:-34.38
High:114.75
Open:110.21
Low:107.09
Close:112.53
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.13
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:71.65
PE(LYR):-34.46

Loading ...

Rhythm Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $100 From $110

THOMSON REUTERS
·
Mar 18

These Stocks Are Today's Movers: Nvidia, Oklo, Delta, Carnival, Uber, Honeywell, Elbit, and More -- Barrons.com

Dow Jones
·
Mar 17

Rhythm Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $136 From $142

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Mar 17

Guggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Mar 17

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Merck & Company (MRK)

TIPRANKS
·
Mar 17

RBC Lowers Price Target on Rhythm Pharmaceuticals to $130 From $140, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Mar 17

Rhythm Pharmaceuticals Inc : Needham Cuts Target Price to $130 From $139

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals price target lowered to $152 from $176 at Citizens

TIPRANKS
·
Mar 17

Rhythm Pharmaceuticals Inc : RBC Cuts Target Price to $130 From $140

THOMSON REUTERS
·
Mar 17

Stocks to Watch: Lensar, Rhythm Pharmaceuticals, TruBridge, Kaltura

Dow Jones
·
Mar 17

BRIEF-Rhythm Pharmaceuticals Announces Topline Results From Phase 3 Emanate Trial

Reuters
·
Mar 17

Rhythm Pharma Exec Says the 2022‑Launched Trial Was Partly Affected by the Rise of Glp‑1 Drugs, Which May Have Contributed to High Patient Dropout Rates

THOMSON REUTERS
·
Mar 17

Rhythm Pharma Exec Says Most Placebo Patients Stopped Treatment by Choice, While Most Setmelanotide Patients Discontinued Because of Side Effects

THOMSON REUTERS
·
Mar 17

Rhythm Pharma Exec Says Emanate Trail Saw an Avg 40% to 60% Patient Dropout Rate Across All Groups - Conf Call

THOMSON REUTERS
·
Mar 17

Rhythm reports EMANATE trial substudies did not meet primary endpoints

TIPRANKS
·
Mar 17

Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial

Reuters
·
Mar 17

Rhythm Pharmaceuticals Shares Fall About 13% to $78.58 After the Bell Following Announcement That Emanate Phase 3 Trial Didn't Meet Primary Endpoints

THOMSON REUTERS
·
Mar 17

Rhythm Pharmaceuticals reports Phase 3 EMANATE trial misses primary endpoints for setmelanotide across four genetic substudies

Reuters
·
Mar 17

Rhythm Pharmaceuticals Inc: Plans to Continue Analysis of Emanate Dataset & Evaluate Potential Clinical Development Paths Forward

THOMSON REUTERS
·
Mar 17